Weight loss

Lindora Launches Inaugural Challenge to Kickstart Weight Loss Journeys

Retrieved on: 
Monday, April 22, 2024
General Health, Fitness & Nutrition, Health, Other Health, Science, Wellness, Countdown, Princess, Weight loss, Immunity, Metabolism, Tourism

Lindora , a leading provider of medically guided weight loss and metabolic health solutions, has officially launched its first Countdown to Summer Challenge .

Key Points: 
  • Lindora , a leading provider of medically guided weight loss and metabolic health solutions, has officially launched its first Countdown to Summer Challenge .
  • Through April 30th, Lindora invites clients to start a wellness membership and join a 10-week weight loss program to achieve a personal goal, ahead of summer, and with support from Lindora medical staff and member community.
  • “At Lindora, our medically-guided wellness memberships and 10-week weight loss programs have helped hundreds of thousands of clients set and achieve their weight loss goals,” said Dr. Amy Lee, Chief Medical Advisor for Lindora.
  • “As we continue our mission to lead the metabolic health movement, we’re thrilled to launch the Lindora Countdown to Summer Challenge to encourage individuals to start their weight loss journey at Lindora where our science, our staff and our community offer support throughout the program.

United States Telehealth Weight Loss Market Report 2024-2028: Impacts of COVID and GLP-1 Meds Featuring Weight Watchers, Noom, Ro.co, , AmWell, Amazon, Teladoc, Form Health, Form Health Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, April 19, 2024
Fitness & Nutrition, Health, Telemedicine, Virtual Medicine, Internet, PEW, Pharmacy, Hers, McKinsey & Company, Noom, NIH, Map, Truist, Research, Weight loss, Growth, Obesity, PayScale, BLS, COVID-19, Physician, Indeed, Pew Research Center, Investment, Tutoring

This new Marketdata report presents an analysis of weight loss programs provided by various telehealth/telemedicine platforms.

Key Points: 
  • This new Marketdata report presents an analysis of weight loss programs provided by various telehealth/telemedicine platforms.
  • Telehealth soared during the pandemic in 2020 as consumers stayed home and communicated with their physicians via Zoom video calls and by phone, email and chat.
  • Then, in 2021-2023, as demand for the GLP-1 weight loss medications took off, many of these telehealth providers added weight loss plans based on access to these drugs, plus support.
  • Includes profiles for: Weight Watchers Clinic, LifeMD/Medifast, Noom, Ro.co, Calibrate Health, AmWell, Amazon Health, Teladoc, Form Health (Lilly Direct), Hims & Hers, Mochi Health, Form Health, and 10 more.

Metsera Launches to Lead the Next Generation of Medicines for Obesity and Metabolic Diseases

Retrieved on: 
Thursday, April 18, 2024
Health, Fitness & Nutrition, General Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, GV, Digestion, Capital, ARCH Venture Partners, Reproduction, FRS, Weight loss, Research, Imperial College London, Obesity, Patient, DSM-IV codes, Peptide, Metabolism, Head, Drug development, Fine chemical

Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, announced its launch today.

Key Points: 
  • Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, announced its launch today.
  • “Metsera was purpose-built over the last two years to get ahead of the innovation curve in one of the largest and fastest growing markets in the history of biopharma,” said Clive Meanwell, chief executive officer of Metsera.
  • “We have assembled a portfolio of long-acting injectable and oral agents to address multiple next-generation weight loss goals.
  • “Through optimized combinations of injectable and oral peptides, we aim to establish a cycle of continuous and responsive innovation to address a growing worldwide obesity crisis.”

Green Circle Life Expands Availability of Healthy Weight for Life Program for the SmartFHR™ Platform

Retrieved on: 
Tuesday, April 16, 2024
Technology, Professional Services, Health, Pharmaceutical, Health Technology, Health Insurance, Data Analytics, Software, Fitness & Nutrition, Human Resources, Telemedicine, Virtual Medicine, Snack, ROI, Pharmacy, NCQA, AutoZone, HR, Eli Lilly, Insurance, Compensation, Partnership, Weight loss, Doctor of Philosophy, Quality assurance, Pharmacotherapy, Prescription, Obesity, Exercise, Life, Novo Nordisk, Diet, GCL, Workforce, National Committee, Quality of life

HWFL is an employer-offered weight management program designed to work with individuals to set realistic goals, attain and maintain their desired weight through lifestyle changes.

Key Points: 
  • HWFL is an employer-offered weight management program designed to work with individuals to set realistic goals, attain and maintain their desired weight through lifestyle changes.
  • The program, which provides private, personalized coaching, encourages users to engage in physical activities, nutritional adjustments and monitor weight outcomes.
  • Dinesh Sheth, founder and CEO of Green Circle Life, emphasized, “Health and wellness are at the forefront of HR challenges, and obesity is a national epidemic.
  • Healthy weight is not a 'one and done' 'one size fits all' proposition but rather a constantly evolving journey.

Ark Clinical Research Announces Advancing Accessibility for Obesity Through Innovative Research Trials on GLP-1 drugs

Retrieved on: 
Tuesday, April 16, 2024
Research, Fitness & Nutrition, Clinical Trials, Biotechnology, Managed Care, Health, Pharmaceutical, General Health, Science, FDA, Organization, Diabetes, Learning, Hope, Statistics, Weight loss, Obesity, Exercise, Patient, Diet, Magnetic resonance, Ark, Pharmaceutical industry

Ark Clinical Research (“Ark”) is advancing accessible solutions for obesity and obesity-related diseases through clinical research and a free health clinic, which administers health assessments and manages patient care.

Key Points: 
  • Ark Clinical Research (“Ark”) is advancing accessible solutions for obesity and obesity-related diseases through clinical research and a free health clinic, which administers health assessments and manages patient care.
  • While the clinical research organization conducts Phase I-IV clinical trials in various therapeutic areas, the company is particularly focused on weight loss studies and accessibility of these drugs for those in need, particularly for low-income and minority patients.
  • While these studies are placebo controlled, they can provide another avenue for GLP-1 drugs or other obesity drugs.
  • If you are interested in learning more about Ark Clinical Research, please contact Samira Moran, CEO by phone at 310-710-2985 or by email at [email protected] .

Lindora, Leader in Wellness Solutions, Signs First Wave of Multi-Unit Franchise Agreements in Key Markets

Retrieved on: 
Monday, April 15, 2024
Professional Services, Business, Health, Other Health, Fitness & Nutrition, General Health, BFT, Internal medicine, Pilates, Weight loss, Partnership, Dance, AKT, Yoga, HRT, Exercise, Acquisition, Medicine, Hill of Row, Boxing, Marketing, Running, Hormone replacement therapy, Pharmaceutical industry

Following its acquisition by Xponential Fitness , Lindora has franchise agreements with owners from diverse backgrounds including technology, software development, real estate, marketing and sales, personal training, and finance.

Key Points: 
  • Following its acquisition by Xponential Fitness , Lindora has franchise agreements with owners from diverse backgrounds including technology, software development, real estate, marketing and sales, personal training, and finance.
  • As the largest global franchisor of health and wellness brands, Xponential brings unparalleled experience and resources to support Lindora franchisees.
  • Founded in 1971 in Southern California, Lindora is a leading provider of medically guided weight management programs and wellness solutions.
  • Lindora is headquartered in Irvine, CA and backed by Xponential Fitness, the largest franchisor of boutique health and wellness brands.

NABP Report Explores How Illegal Online Sellers Exploit Consumer Demand for Weight Loss Drugs

Retrieved on: 
Wednesday, April 24, 2024
Online, Government agency, Risk, Food, Crime, Insurance, Weight loss, Liraglutide, National Association, Obesity, Partnership, Type 2 diabetes, NABP, Organization, Pharmaceutical industry

Unfortunately, because of the drugs' popularity, criminals have seized the opportunity to illegally sell the drugs online, putting patients at risk.

Key Points: 
  • Unfortunately, because of the drugs' popularity, criminals have seized the opportunity to illegally sell the drugs online, putting patients at risk.
  • NABP's RogueRx Activity Report explores illegal activity that has followed the rise of injectable weight loss drugs.
  • Illegal online sellers are exploiting this demand by offering substandard and falsified GLP-1 agonists to vulnerable patients.
  • Learn how you can warn patients against illegal online sellers of GLP-1 agonists by reading the RogueRx Activity Report .

Enormous Demand for Weight-Loss Drugs Drives Up Total U.S. Prescription Spending

Retrieved on: 
Wednesday, April 24, 2024
FDA, Mayo Clinic, Adalimumab, Cancer, Pharmacy, Hospital, Crohn's disease, COVID, Tichy, Biosimilar, Diabetes, Publishing, Weight loss, Growth, Neurology, Society, ASHP, Rheumatoid arthritis, Pharming, Inflation, Semaglutide, Injection, Pharmaceutical industry

BETHESDA, Md., April 24, 2024 /PRNewswire/ -- Blockbuster growth in weight-loss drugs was the main driver of a 13.5% increase in spending on prescription medications in the U.S. in 2023, according to ASHP's (American Society of Health-System Pharmacists) report, National Trends in Prescription Drug Expenditures and Projections for 2024.  By contrast, hospital drug spending dipped slightly as the pandemic ended and remdesivir injections were replaced by less-costly oral COVID treatments.

Key Points: 
  • By contrast, hospital drug spending dipped slightly as the pandemic ended and remdesivir injections were replaced by less-costly oral COVID treatments.
  • Growth in weight-loss drugs was the main driver of a 13.5% increase in spending on prescription medications in 2023.
  • Spending on weight-loss drugs — originally marketed as diabetes treatments —will likely continue to climb as supplies catch up with the huge demand, the report predicted.
  • "Pharmacy and health-system leaders should persist in their proactive management and continue to anticipate disruptions that may affect drug spending."

TELUS Health 2024 Drug Trends Report: Diabetes medications maintain top reimbursed expense position; ADHD drugs surge

Retrieved on: 
Tuesday, April 23, 2024
Pharmacy, Policy, Biosimilar, Health, Diabetes, Weight loss, Health Canada, Telus Health, Conference, ADHD, Depression, Prescription, Senior, Attention deficit hyperactivity disorder, Type 2 diabetes, Patient, Pharmacare, Prediabetes, Growth, Prevalence, Heart failure, Health insurance

TORONTO, April 23, 2024 /CNW/ - TELUS Health revealed today the results of its 2024 Drug Data Trends and National Benchmarks Report at its 20th annual TELUS Health Conference, running today and April 30.

Key Points: 
  • TORONTO, April 23, 2024 /CNW/ - TELUS Health revealed today the results of its 2024 Drug Data Trends and National Benchmarks Report at its 20th annual TELUS Health Conference, running today and April 30.
  • Diabetes medications remain the leading drug category for eligible private insurance claims for the second consecutive year and noteworthy spikes were observed in claims for attention deficit hyperactivity disorder (ADHD) medications, particularly among young adults.
  • Health Canada reports that over three million people in Canada, 8.9 per cent of the population, have diabetes, with a yearly prevalence growth of 3.3 per cent.
  • "Biosimilars continue to offer a significant opportunity for cost savings for private payors," adds Caroline Le Pottier, Pharmacist, TELUS Health.

MyFitnessPal Announces Tools and Content to Support the Health and Wellness of Members on GLP-1 Medications

Retrieved on: 
Tuesday, April 23, 2024
Facial muscles, Health, CDN, Weight loss, Collection, Atrophy, Google Play, Exercise, Patient, Mental health, Food, MyFitnessPal, Malnutrition, Sleep, App Store (iOS/iPadOS), Ageing, Dietary supplement

NEW YORK, April 23, 2024 /PRNewswire/ -- Today, MyFitnessPal, the number one global food and nutrition tracking app, introduced a variety of new tools and content developed to support the health and wellness of their members on GLP-1 medications (e.g., Mounjaro®, Ozempic®, Wegovy®, Zepbound™ ) to ensure they are offered a holistic approach that optimizes success. In addition to tracking their weight loss, the new updates and tools offered by MyFitnessPal empower members to develop and maintain consistency and proper nutrition while on these medications. Members will have access to a library of exercise videos to help maintain muscle, along with encouragement to eat and log high quality, nutrient-dense food to support the development of consistency and lasting healthy behaviors.

Key Points: 
  • In addition to tracking their weight loss, the new updates and tools offered by MyFitnessPal empower members to develop and maintain consistency and proper nutrition while on these medications.
  • MyFitnessPal built the free in-app plan in response to a survey2 that found 34% of the people say they would benefit from regular updates or content about GLP-1 medications as related to nutrition.
  • For more information on MyFitnessPal, visit www.myfitnesspal.com or download the app for free via the App Store or Google Play .
  • 1,2 Survey fielded by MyFitnessPal in January 2024 with 2000 people aged 18-64 across the United States.